Literatur

1. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 27;355(9218): 1869-74

2. Amin AM, Creveling CR, Lowe MC. Immunohistochemical localization of Catechol methyl-transferase in normal and cancerous breast tissues of mice and rats. J. Natl. Cancer Inst. 1983: 70(2): 337-342

3. Amorino GP, Freeman ML, Choy H (2000) Enhancement of radiation effects in vitro by the estrogen metabolite 2-methoxyestradiol. Radiat Res; 153: 384-391.

4. Arbiser JL, Panigrathy D, Klauber N, Rupmick M, Flynn E, Udagawa T, D'Amato RJ (1999) The antiangiogenic agents TNP-470 and 2-Methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol; 40 (6Pt1): 925-929.

5. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP(1998) 2 -Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun; 247(3): 616-9.

6. Attalla H. Mäkelä T.P. Adlercreutz H. Andersson L.C (1996) 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem biophys res comm; 228. 467-473.

7. Banerjeei SK, Zoubine MN, Sarkar DK, Weston AP, Shah JH, Campbell DR (2000) 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor. Anticancer Res. Jul-Aug; 20(4): 2641-5.

8. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 1997: 15(23): 2767-2772

9. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol. (Copenhagen) 1983: 103, 282-288

10. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993 Sep 15; 85(18): 1483-92

11. Bookstein R., Demers W, Gregory R., Maneval D., Park J., Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Seminars in Oncology 23 (1): 66-77, 1996

12. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21Waf1. Pathol. Biol. (Paris) 2000: 48(3): 190-202

13. Bruix J, Castells A, Bru C. Review: Diagnosis and treatment of hepatocellular carcinoma. A western perspective. The Cancer Journal 1992: 5(1)

14. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002 Nov 6; 531(2): 141-51

15. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS. P53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. Biol. Chem. 1999: 274(21): 15237-15244

16. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994 Dec ; 106(6 Suppl) : 377S-381S.

17. Carothers AM, Hughes SA, Ortega D, Bertagnolli MM. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett 2002 Dec 10; 187(1-2): 77-86.

18. Cassidy J, Bissett D, Spence Obe RAJ. Eds. Oxford Handbook of Oncology. Oxford University Press Inc. New York. 2002.

19. Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002 Sep 15; 100(6): 2187-94

20. Chen X, Ko LJ, Jayaraman L, Prives C. P53 levels, functional domains and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 1996: 10: 2438-2451

21. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990 Oct; 5(10): 1603-10

22. Choi SW, Hytiroglou P, Geller SA, Kim SM, Chung KW, Park DH, Theise ND, Thung SN. The expression of p53 antigen in primary malignant epithelial tumors of the liver: an immunohistological study. Liver 1993: 13: 172-176

23. Cristiano R.J., Bo X., Nguyen D., Schumacher G., Kataoka M., Spitz F.R., Roth J.A. Viral and nonviral gene delivery vectors for cancer gene therapy. Cancer Detection and prevention. 22(5): 445-454 (1998)

24. Curtin NJ, Harris AL, James OF, Bassendine MF. Inhibition of growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717. Br. J. Cancer 1986: 53(3): 361-368

25. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem. Jun 9; 38(12): 2041-9.

26. D´Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2- Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA 1994: Vol. 91: 3964-3968

27. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001 Sep 15; 61(18): 6716-22

28. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989 Oct 1; 111(7): 592-603

29. Dingli D, Timm M, Russell SJ, Witzig TE, Rajkumar SV. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res 2002 Dec; 8(12): 3948-54

30. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991 Jan 16; 83(2): 97-104.

31. Doll R, Peto R. The causes of cancer:quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981 Jun; 66(6): 1191-308

32. Dubey RK, Gillespie DG, Keller PJ, Imthurn B, Zacharia LC, Jackson EK. Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells. Hypertension 2002 Feb; 39(2 Pt 2): 418-24

33. Dunn JF (1983) Transport of estrogens in human plasma. In: G.R. Merriam and M.B. Lipsett (eds.), Catechol Estrogens 167-176. New York: Raven Press.

34. El-Naggar AK. The Cancer Journal 1992: 5(6)

35. Feigelson HS, Henderson BE (1996) Estrogens and breast cancer. Carcinogenesis. Nov;17(11): 2279-84. Review. No abstract available.

36. Feitelson MA. Hepatitis B x antigen and p53 in the development of hepatocellular carcinoma. J. Hepatobiliary Pancreat. Surg. 1998: 5(4): 367-374

37. Fiel MI, Min A, Gerber MA, Faire B, Schwartz M, Thung SN. Hepatocellular carcinoma in long-term oral contraceptive use. Liver 1996: 16: 372-376

38. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature; 368: 237-239.

39. Gelbke HP, Knuppen R (1976) The excretion of five different 2-hydroxyoestrogen monomethyl ethers in human pregnancy urine. J Steroid Biochem; 7: 457-463.

40. Gilliam AD, Watson SA. Emerging biological therapies for pancreatic carcinoma. Eur J Surg Oncol 2002 Jun ; 28(4) : 370-8

41. Ginsberg RJ, Vokes EE, Raben A. Non small cell lung cancer. Aus: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer, Priniples and practice of oncology. 1997; 5th edition Lippincott-Raven 858-911.

42. Golab J, Nowis D, Skrzycki M, Czeczot H, Baranczyk-Kuzma A, Wilczynski GM, Makowski M, Mroz P, Kozar K, Kaminski R, Jalili A, Kopec' M, Grzela T, Jakobisiak M. Antitumor Effects of Photodynamic Therapy Are Potentiated by 2-Methoxyestradiol. A SUPEROXIDE DISMUTASE INHIBITOR. J Biol Chem 2003 Jan 3; 278(1): 407-14

43. Golebiewska J, Rozwadowski P, Spodnik JH, Knap N, Wakabayashi T, Wozniak M. Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells. Acta Biochim Pol 2002; 49(1): 59-65

44. Guinn BA, Padua RA. Review: p53 A role in the initiation and progression of leukemia? Cancer Journal 1997: 8: No. 4

45. Hahn EG, Gauss-Muller V, Hornberger M, Kalbfleisch H, Deinhardt F. Solid tumours of human primary hepatocellular carcinoma cell-lines in hypothymic mice: a model for biochemical and therapeutic studies (author´s transl). Z. Gastroenterol. 1982: 20(3): 168-173

46. Hamada K. Alemany R. Zhang W.W. Hittelman W.N. Lotan R. Roth J.A. Mitchell M.F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Research. 56(13): 3047-3054, (1996).

47. Hamel E, Lin CM, Flynn E, D'Amato RJ (1996) Interactions of 2-methoxyestradiol, an endogeneous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry; 35: 1304-1310.

48. Hayashi H, Sugio K, Matsumata T, Adachi E, Urata K, Tanaka S, Sugimachi K. The mutation of codon 249 in the p53 gene is not specific in Japanese hepatocellular carcinoma. Liver 1993: 13: 279-281

49. Heise C, Sampson-Johannes A., Williams A, McCormack F, Von Hoff DD and Kirn DH, ONYX-015, an E1B gene attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine 3 6 (1997), pp. 639-645.

50. Heng-Liang L, Liu TY, Chi CW. The effect of 2-methoxyestradiol on cell cycle distribution, caspase activation and DNA fragmentation in gastric cancer cells [Abstract] Proc. Am. Assoc. Cancer Res 2000; 41; 5233: 824.

51. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000 Sep 21; 407(6802): 390-5

52. Huober JB, Nakamura S, Meyn R, Roth JA, Mukhopadhyay T. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000 Nov 1; 48(4): 1127-37

53. Jacobs AD. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer 2002 Aug 15; 95(4 Suppl): 923-7.

54. Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang WW, Roth JA, Tanaka N. P53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene 1997: 15(16): 1903-1909

55. Kang KH, Kim WH, Choi KH. P21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of bcl-2 in human hepatocarcinoma cells. Exp. Cell. Res. 1999: 253(2): 403-412

56. Kataoka M, Schumacher G, Cristiano RJ, Atkinson EN, Roth JA, Mukhopadhyay T. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 1998; 58(21): 4761-5.

57. Kawakami K, Tsukuda M, Mizuno H, Nishimura G, Ishii A, Hamajima K. Alteration of the bcl-2/bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res. 1999: 19(5B): 3972-3932

58. Kinuya S, Kawashima A, Yokoyama K, Kudo M, Kasahara Y, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. Eur J Nucl Med 2001 Sep; 28(9): 1306-12

59. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. Jan 1; 57(1): 81-6

60. Kliche KO, Hoffken K (1999) The role of apoptosis in hematologic malignancies and modulation of apoptosis as a new therapeutic approach. J Cancer Res Clin Oncol.; 125(3-4): 226-31.

61. Knudson CM, Korsmeyer SJ. Bcl-2 and bax protein function independently to regulate cell death. Nat. Genet. 1997: 16(4): 358-363

62. Kumar AP, Garcia GE, Slaga TJ. 2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001 Jul; 31 (3): 111-24

63. Lane DP, Crawford LV. T-antigen is bound to host protein in SV 40 transformed cells. Nature 1979: 278: 261-263

64. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002 Jul 1; 62(13): 3691-7

65. Lewin: Genes, Oxfort University Press, Oxford, New York, Tokyo 1998.

66. Lin HL, Liu TY, Chau GY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000: 89(5): 983-994

67. Lin HL, Liu TY, Wu CW, Chi CW. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 2001 Aug 1; 92(3): 500-9

68. Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003 Jan 10; 72(8): 877-83.

69. Lippert TH, Seeger H, Mueck AO. The significance of estrogen metabolism for hormone-dependent neoplasms from the clinical-pharmacological viewpoint. Arzneimittelforschung 1999: 49(8): 649-662

70. Lottering ML, Haag M, Seegers JC (1992) Effects of 17 beta-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res. Nov 1;52(21): 5926-32.

71. Lui W, Lin H, Chau G, Liu T, Chi C (2000) Male predominance in hepatocellular carcinoma: new insight and a possible therapeutic alternative. Med Hypotheses. Oct;55(4): 348-350.

72. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, Brown SE (1976) Estrogens and endometrial cancer in a retirement community. N Engl J Med. Jun 3;294(23): 1262-7.

73. Maran A, Zhang M, Kennedy AM, Sibonga JD, Rickard DJ, Spelsberg TC, Turner RT. 2-methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone 2002 Feb; 30(2): 393-8

74. Martucci CP, Fishman J (1993) P450 enzymes of estrogen metabolism. Pharmacol Ther. Feb-Mar;57(2-3): 237-57. Review.

75. McCormick DL, Johnson WD, Pribluda VS, Green SJ, Tomaszewski JE, Smith AC (2000) Preclinical development of 2-methoxyestradiol (2ME2, NSC-659853). [Abstract] Proc. Am. Assoc. Cancer Res; 41;2080: 328.

76. McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD Jr, Kurland LT (1977) Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol. Mar 15;127(6): 572-80.

77. McDonnell TJ, Marin MC, Hsu B, Brisbay SM, McConnell K, Tu SM, Campbell ML, Rodriguez-Villanueva J. The bcl-2 oncogene: apoptosis and neoplasia. Radiat. Res. 1993: 136(3): 307-312

78. McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer 2002 Aug 15; 95(4 Suppl): 933-40

79. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001 Mar; 8(1): 3-9

80. Merriam GR, MacLusky NJ, Picard MK, Naftolin F. Comparative properties of the catechol estrogens, I: Methylation by catechol-o-methyltransferase and binding to cytosol estrogen receptors. Steroids 1980: 36(1): 1-11

81. Miller KD, Murry DJ, Curry E, Haney LG, McClaskey N, Storniolo AM, Phillips E, Pribluda V, Gubish ER, Sledge GW Jr. A phase I study of 2-methoxyestradiol (2ME2) plus docetaxel (D) in patients (pts) with metastatic breast cancer (MBC) Annual meeting of the American Association of Clinical Oncology 2002 May 18-21 , Abstract No: 442 Category: Phase I Trials Orlando, FL, USA

82. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cell after wild-type p53 activation by methoxyestradiol. Oncogene 1997: 14: 379-384

83. Mukhopadhyay T, Roth JA. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 1998: 17(2): 241-246

84. Nakagawa-Yagi Y, Ogane N, Inoki Y, Kitoh N (1996) The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic neuronal cell death in vitro. Life Sci; 58(17): 1461-7

85. Negro F, Papotti M, Pacchioni D, Galimi F, Bonino F, Bussolati G. Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridization. Liver 1994: 14: 213-219

86. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001 Nov 10; 358(9293): 1565-6.

87. Nielsen L.L., Gurnani M., Syed J., Dell J., Hartman B., Cartwright M., Johnson R.C. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer - efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models. Human gene therapy 9(5): 681-694 (1998)

88. Parkin DM, Pisani P, Lopez AD, Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 1994 Nov 15; 59(4): 494-504

89. Peters M, Blinn G, Jostock T, Schirmacher P, Meyer zum Buschenfelde KH, Galle PR, Rose-John S. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 2000 Dec; 119(6): 1663-71

90. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev.; 15(1): 17-35. Review. No abstract available

91. Poutanen M, Isomaa V, Peltoketo H, Vihko R (1995) Regulation of oestrogen action: role of 17 beta-hydroxysteroid dehydrogenases. Ann Med. Dec;27(6): 675-82. Review.

92. Pribluda VS, Green SJ (1998) A good estrogen. Science; 280: 987-988.

93. Pritchard KI (2000) Current and future directions in medical therapy for breast carcinoma: endocrine treatment. Cancer Jun 15;88(12 Suppl): 3065-72

94. Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA, Roos BA. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 2001 Aug 3; 285(5): 1259-66

95. Qanungo S, Basu A, Das M, Haldar S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene 2002 Jun 13; 21(26): 4149-57

96. Reiser F, Way D, Bernas M, Witte M, Witte C (1998) Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Proc Soc Exp Biol Med; 219(3): 211-216.

97. Ries L, Hankey B, Miller B, Hartman A, Edwards B, eds. Cancer statistics review 1973-1988. Bethesda: National Cancer Institue, 1991: Table VI-21.

98. Robinson MR, Baffi J, Yuan P, Sung C, Byrnes G, Cox TA, Csaky KG. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization. Exp Eye Res 2002 Feb; 74(2): 309-17

99. Rosenberg L. Pancreatic cancer:a review of emerging therapies. Drugs 2000 May; 59(5): 1071-89

100. Roth J.A. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wild-type p53 and cisplatin. Human Gene Therapy. 7(8): 1013-1030, (1996)

101. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996 Sep; 2(9): 985-91

102. Runnebaum I.R., Hawighorst T, Möbus V.J., Kreienberg R., Schering-Plough Ovarian Cancer Clinical Study Group. Adenovirally mediated p53 gene therapy in a phase I trial for ovarian cancer: J Cancer Res Clin Oncol 124 (Suppl) R48: 12.08.01 (1998)

103. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993 May 15; 53(10 Suppl): 2379-85

104. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenc P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001: 48(1): 103-109

105. Schumacher G, Bruckheimer EM, Beham AW, Honda T, Brisbay S, Roth JA, Logothetis C, McDonnell TJ. Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int. J. Cancer 2001: 91(2): 159-66

106. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T (1999) Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res; 5(3): 493-9.

107. Schumacher G, Scheunert S, Nuessler A.K, Weber A, Mueller A, Platz K.P, Mukhopadhyay T, Neuhaus P. 2-Methoxyestradiol inhibits tumor growth and induces apoptosis in human hepatoma cells. Proc. Am. Assoc. Cancer Res. (2000) 4909: 772-773.

108. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma:review of the randomised clinical trials. Lancet Oncol 2002 Oct; 3(10): 593-603

109. Seegers JC, Aveling ML, Van Aswegen CH, Cross M, Koch F, Joubert WS (1989) The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem. Jun; 32(6): 797-809

110. Seegers JC, Lottering ML, Grobler CJ, van Papendorp DH, Habbersett RC, Shou Y, Lehnert BE (1997) The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol. Jul; 62(4): 253-67.

111. Slebos R, Kibbelaar R, Dalesio O. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561.

112. Sledge GW Jr., Miller KD, Haney LG, Nguyen DD, Storniolo AM, Phillips EN, Pribluda V, Gubish ER, A phase I study of 2-methoxyestradiol (2ME2) in patients (pts) with refractory metastatic breast cancer. Annual meeting of the American Association of Clinical Oncology (ASCO) 2002, May 18-21, Abstract No: 441 Category: Phase I Trials. Orlando, FL, USA

113. Spitz F.R. Nguyen D. Skibber J.M. Meyn R.E. Cristiano R.J. Roth J.A. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clinical Cancer Research. 2(10): 1665-1671, (1996).

114. Steegenga WT, van der Eb AJ, Jochemsen AG. How phosphorylation regulates the activity of p53. J. Mol. Biol. 1996: 263(2): 103-13

115. Strom SC, Dorko K, Thompson MT, Pisarov LA, Nussler AK. (1993) Large scale isolation and culture of human hepatocytes. In: Franco D., Boudjema K., Varet B, eds. Ilots de Langerhans et hépatocytes. Vers une utilisation thérapeutique. Chapter 17. Les Editions Inserm: 195-205.

116. Stuver SO. Towards global control of liver cancer ? Seminars in Cancer Biology 1997 : 8(4): 299-306

117. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001 Apr 15; 61(8): 3369-72.

118. Swisher SG, Roth JA. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am 2002 Jul; 11(3): 521-35.

119. Tang ZY. Hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2000: 15: 1-7

120. Tsukamoto A, Kaneko Y, Yoshida T, Han K, Ichinose M, Kimura S. 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells. Biochem. Biophys. Res. Commun. 1998: 9: 248(1): 9-12.

121. Tsutsui T, Tamura Y, Hagiwara M, Miyachi T, Hikiba H, Kubo C, Barrett JC (2000) Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen. Carcinogenesis. Apr;21(4): 735-40.

122. Turner RT, Evans GL. 2-Methoxyestradiol inhibits longitudinal bone growth in normal female rats. Calcif. Tissue Int. 2000: 66(6): 465-469.

123. Verdier-Pinard P, Wang Z, Mohanakrishnan AK, Cushman M, Hamel E (2000) A steroid derivative with paclitaxel-like effects on tubulin polymerization. Mol Pharmacol; 57: 568-575.

124. Wang SH, Myc A, Koenig RJ, Bretz JD, Arscott PL, Baker JR. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces thyroid cell apoptosis. Mol. Cell. Endocrinol. 2000: 165(1-2): 163-172.

125. Wassberg E (1999) Angiostatic treatment of neuroblastoma. Ups J Med Sci; 104: 1-24.

126. Weber A, Wahn U, Renz H. Superantigen-induced T cell death by apoptosis: analysis on a single cell level and effect of IFN-( and IL-4 treatment. Int. Arch. Allergy Immunol. 2000: 12: 215-223.

127. WHO World Health Report: Mortality Database Germany 1997

128. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can. J. Gastroenterol. 2000: 14(8): 703-709

129. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997; 51(6): 951-62.

130. Zhu BT, Conney AH (1998) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. Jun 1;58(11): 2269-77. Review.

131. Ziel HK, Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. Dec 4;293(23): 1167-70.

132. Zoubine MN, Weston AP, Johnson DC, Campbell DR, Banerjee SK (1999) 2-methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression. Int J Oncol. Oct;15(4): 639-46.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
28.11.2006